These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36119532)

  • 21. Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy.
    Zheng K; Zhu X; Xu L; Cao G; Niu C; Yan X; Xu D; Liu W; Bao Q; Wang L; Wang K; Xing B; Wang X
    Front Oncol; 2024; 14():1420956. PubMed ID: 39234395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report.
    Cheng X; Li X; Yang X; Fang S; Wang Z; Liu T; Zheng M; Zhai M; Yang Z; Shen T
    Cureus; 2023 Jul; 15(7):e42347. PubMed ID: 37621810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial.
    Dong Q; Diao Y; Sun X; Zhou Y; Ran J; Zhang J
    BMJ Open; 2022 Apr; 12(4):e049992. PubMed ID: 35379611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 28. PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.
    Yang J; Xing P; Kong Y; Xu M; Zhang L
    Front Oncol; 2023; 13():1078915. PubMed ID: 37188188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer.
    Wang T; Shao Q; Xiao C; Liu L
    Front Oncol; 2023; 13():1124730. PubMed ID: 36998454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
    Moretto R; Elliott A; Zhang J; Arai H; Germani MM; Conca V; Xiu J; Stafford P; Oberley M; Abraham J; Spetzler D; Rossini D; Antoniotti C; Marshall J; Shields A; Lopes G; Lonardi S; Pietrantonio F; Tomasello G; Passardi A; Tamburini E; Santini D; Aprile G; Masi G; Falcone A; Lenz HJ; Korn M; Cremolini C
    J Natl Cancer Inst; 2022 Feb; 114(2):271-279. PubMed ID: 34469533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
    Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
    Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Impact of Tumor Cell-Intrinsic Expression of Cyclic GMP-AMP Synthase (cGAS)-Stimulator of Interferon Genes (STING) on the Infiltration of CD8
    Nakajima S; Kaneta A; Okayama H; Saito K; Kikuchi T; Endo E; Matsumoto T; Fukai S; Sakuma M; Sato T; Mimura K; Saito M; Saze Z; Sakamoto W; Onozawa H; Momma T; Kono K
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
    Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
    Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.
    Liu Y; Du J; Zhang P; Meng W; Xiao H
    Front Oncol; 2023; 13():1051786. PubMed ID: 36969074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness.
    Xu YJ; Zhang P; Hu JL; Liang H; Zhu YY; Cui Y; Niu P; Xu M; Liu MY
    World J Gastrointest Oncol; 2022 Apr; 14(4):920-934. PubMed ID: 35582108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
    Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
    Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
    Yu W; Tao Q; Zhang Y; Yi F; Feng L
    J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.